论文与基金

订阅

MedSci主页 / 所有栏目 / 论文与基金

知网文献检索可以替代pubmed吗？

2021-10-13 MedSci原创 MedSci原创

文献解读文献查询文献检索文献管理
关注

知网文献精准检索与高效分析整理-问题10

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745981, encodeId=91191e4598154, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 29 17:04:48 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365581, encodeId=6486136558142, content=<a href='/topic/show?id=e87c148e4f0' target=_blank style='color:#2F92EE;'>#Pubmed#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14874, encryptionId=e87c148e4f0, topicName=Pubmed)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611293, encodeId=a82a16112936a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060258, encodeId=53c21060258d0, content=不可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=zerohahaha, createdTime=Wed Oct 13 22:25:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060193, encodeId=2ad710601930a, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0455634424, createdName=ms2000000783665237, createdTime=Wed Oct 13 18:30:40 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-08-29 nakerunner

    #知网#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1745981, encodeId=91191e4598154, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 29 17:04:48 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365581, encodeId=6486136558142, content=<a href='/topic/show?id=e87c148e4f0' target=_blank style='color:#2F92EE;'>#Pubmed#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14874, encryptionId=e87c148e4f0, topicName=Pubmed)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611293, encodeId=a82a16112936a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060258, encodeId=53c21060258d0, content=不可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=zerohahaha, createdTime=Wed Oct 13 22:25:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060193, encodeId=2ad710601930a, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0455634424, createdName=ms2000000783665237, createdTime=Wed Oct 13 18:30:40 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-15 zhangpaul93

    #Pubmed#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1745981, encodeId=91191e4598154, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 29 17:04:48 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365581, encodeId=6486136558142, content=<a href='/topic/show?id=e87c148e4f0' target=_blank style='color:#2F92EE;'>#Pubmed#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14874, encryptionId=e87c148e4f0, topicName=Pubmed)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611293, encodeId=a82a16112936a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060258, encodeId=53c21060258d0, content=不可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=zerohahaha, createdTime=Wed Oct 13 22:25:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060193, encodeId=2ad710601930a, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0455634424, createdName=ms2000000783665237, createdTime=Wed Oct 13 18:30:40 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-15 ms3994565386320060

    #Med#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1745981, encodeId=91191e4598154, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 29 17:04:48 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365581, encodeId=6486136558142, content=<a href='/topic/show?id=e87c148e4f0' target=_blank style='color:#2F92EE;'>#Pubmed#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14874, encryptionId=e87c148e4f0, topicName=Pubmed)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611293, encodeId=a82a16112936a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060258, encodeId=53c21060258d0, content=不可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=zerohahaha, createdTime=Wed Oct 13 22:25:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060193, encodeId=2ad710601930a, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0455634424, createdName=ms2000000783665237, createdTime=Wed Oct 13 18:30:40 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 zerohahaha

    不可以

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1745981, encodeId=91191e4598154, content=<a href='/topic/show?id=d8e9e31540c' target=_blank style='color:#2F92EE;'>#知网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73154, encryptionId=d8e9e31540c, topicName=知网)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a88c35641496, createdName=nakerunner, createdTime=Mon Aug 29 17:04:48 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365581, encodeId=6486136558142, content=<a href='/topic/show?id=e87c148e4f0' target=_blank style='color:#2F92EE;'>#Pubmed#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14874, encryptionId=e87c148e4f0, topicName=Pubmed)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611293, encodeId=a82a16112936a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 15 07:04:48 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060258, encodeId=53c21060258d0, content=不可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64745612835, createdName=zerohahaha, createdTime=Wed Oct 13 22:25:18 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060193, encodeId=2ad710601930a, content=可以可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0455634424, createdName=ms2000000783665237, createdTime=Wed Oct 13 18:30:40 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 ms2000000783665237

    可以可以

    0

相关资讯

新英格兰杂志：早启动透析与晚启动透析的随机对照

一项比较早启动透析与晚启动透析的随机对照试验 A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis　　布鲁斯·A·库珀等 澳大利亚悉尼医学院皇家北海岸医院肾内科等 　　背景 在临床实践中，给V期慢性肾脏病患者启动维持性透析的时机大不相同，在全球有倾向于早启动的趋势。在这项在澳大利亚和新西兰32家